Study of INCB161734 for advanced solid tumors with KRAS G12D mutation
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have an advanced or metastatic solid tumor with a KRAS G12D mutation.
- Your cancer has gotten worse after standard treatment, or you cannot take standard treatments, or you have chosen not to take them.
- You are in good enough physical condition to be up and about (ECOG score 0 or 1).
- You have not had a KRAS G12D inhibitor before.
- You do not have another cancer that required treatment in the last year, a history of organ transplant, or serious uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
This trial tests an experimental drug (BAY 3771249) for people with advanced or metastatic colorectal cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and if it can help shrink tumors.
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
This trial tests two experimental drugs (IN10018 and RNK08954) together for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if this combination can shrink tumors when standard treatments have stopped working.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests two new drugs together for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The treatment may help shrink tumors or slow their growth.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.